The Europe generic drugs market size accounted for USD 113.24 billion in 2025 and is predicted to touch around USD 180.97 billion by 2035, growing at a CAGR of 4.8% from 2026 to 2035. European pharmaceutical industries witness vast generic drug opportunities due to patent expirations of several pharmaceutical drugs.

Europe Generic Drugs Market Statical Scope

The European pharmaceutical legislation aims to strengthen innovation and competitiveness while keeping strict safety standards. It has set certain goals of providing essential treatments and medicines to European patients faster, speeding up supply chains, and streamlining procedures. It makes efforts to introduce new medicines to the market faster and boost innovations. The major pillars behind these innovations are stronger incentives for novel products and safe testing environments for innovative therapies. The European Commission supports better monitoring and coordination to tackle medicine shortages and drive the timely entry of generics into the market.

Europe Generic Drugs Market Share, By Drug Type, 2025 (%)

• Simple Generics- The simple generics segment held a dominating share of 62% in the market in 2025, owing to a strong demand for cost-effective medicines, wide therapeutic applicability, and established manufacturing scalability across Europe.
• Biosimilars- The biosimilars segment held a share of 18% in the market, supported by the increased adoption of biologics alternatives, the growing healthcare pressures, and patent expirations of branded biologics.

Europe Generic Drugs Market Share, By Therapeutic Area, 2025 (%)

• Cardiovascular- The cardiovascular segment represents the market with a share of 28%, driven by the sustained need for generics for long-term generic treatment therapies and the growing risk of cardiovascular health issues.
• Anti-infectives- The anti-infectives segment shows a share of 21%, supported by a continuous burden of infections and strong dependency on affordable antibiotics and antiviral generics.

Europe Generic Drugs Market Share, By Route of Administration, 2025 (%)

• Oral Solids- The oral solids segment held a share of 57%, because of the increased availability of generic tablets and capsule formulations and improved patient adherence to treatments and medications.
• Injectables- The injectables segment highlights a share of 20%, accelerated by the increased use of complex generics and biosimilars , and preference for hospital-based treatments.

Europe Generic Drugs Market Share, By Distribution Channel, 2025 (%)

• Retail Pharmacies- The retail pharmacies segment is booming with a share of 48%, because of the globally expanded pharmacy networks, high consumer accessibility to medicines, and strong adherence to prescriptions.
• Hospital Pharmacies- The hospital pharmacies segment is growing with a revenue share of 28%, owing to the increased hospital admissions of patients and a strong delivery of complex therapies and promising diagnostics.

Top Companies in the Europe Generic Drugs Market

• Sandoz
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Lupin Limited
• Fresenius Kabi AG
• Hikma Pharmaceuticals PLC

Segments Covered in the Report

By Drug Type

• Simple Generics
• Specialty Generics
• Biosimilars
• Complex Generics

By Therapeutic Area

• Cardiovascular
• Oncology
• Anti-Infective
• Central Nervous System
• Endocrine/Metabolic
• Respiratory
• Others

By Route of Administration

• Oral
• Injectable
• Topical
• Inhalable
• Other Route of Administration

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Other Distribution Channel